Asset Details
Do you wish to reserve the book?
Why do cannabinoid receptors have more than one endogenous ligand?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Why do cannabinoid receptors have more than one endogenous ligand?
Do you wish to request the book?
Why do cannabinoid receptors have more than one endogenous ligand?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Why do cannabinoid receptors have more than one endogenous ligand?
2012
Overview
The endocannabinoid system was revealed following the understanding of the mechanism of action of marijuana's major psychotropic principle, Δ9-tetrahydrocannabinol, and includes two G-protein-coupled receptors (GPCRs; the cannabinoid CB1 and CB2 receptors), their endogenous ligands (the endocannabinoids, the best studied of which are anandamide and 2-arachidonoylglycerol (2-AG)), and the proteins that regulate the levels and activity of these receptors and ligands. However, other minor lipid metabolites different from, but chemically similar to, anandamide and 2-AG have also been suggested to act as endocannabinoids. Thus, unlike most other GPCRs, cannabinoid receptors appear to have more than one endogenous agonist, and it has been often wondered what could be the physiological meaning of this peculiarity. In 1999, it was proposed that anandamide might also activate other targets, and in particular the transient receptor potential of vanilloid type-1 (TRPV1) channels. Over the last decade, this interaction has been shown to occur both in peripheral tissues and brain, during both physiological and pathological conditions. TRPV1 channels can be activated also by another less abundant endocannabinoid, N-arachidonoyldopamine, but not by 2-AG, and have been proposed by some authors to act as ionotropic endocannabinoid receptors. This article will discuss the latest discoveries on this subject, and discuss, among others, how anandamide and 2-AG differential actions at TRPV1 and cannabinoid receptors contribute to making this signalling system a versatile tool available to organisms to fine-tune homeostasis.
Publisher
The Royal Society
Subject
/ Animals
/ Arachidonic Acids - metabolism
/ Arachidonic Acids - pharmacology
/ Cannabinoid Receptor Agonists - metabolism
/ Cannabinoid Receptor Agonists - pharmacology
/ Endocannabinoids - metabolism
/ Endocannabinoids - pharmacology
/ Enzymes
/ Humans
/ Ligands
/ Neurons
/ Pain Perception - drug effects
/ Polyunsaturated Alkamides - metabolism
/ Polyunsaturated Alkamides - pharmacology
/ Receptor, Cannabinoid, CB1 - agonists
/ Receptor, Cannabinoid, CB1 - metabolism
/ Receptor, Cannabinoid, CB2 - agonists
/ Receptor, Cannabinoid, CB2 - metabolism
/ Review
/ Transient Receptor Potential Vanilloid Type-1
